All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 (TPS >50%) smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IV (metastatic) Teff high Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 026 (PDL1>1%), 2016 1.07 [0.86; 1.33]
CheckMate 026 (PDL1>5%), 2016 1.02 [0.80; 1.30]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.78 [0.60; 1.02]
EMPOWER lung1 (all population), 2021 0.68 [0.53; 0.87]
EMPOWER lung1 (PDL1>50%), 2021 0.57 [0.42; 0.77]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06]
IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88]
IMpower-130 (all population), 2019 0.80 [0.65; 0.99]
IMpower-130 (WT), 2019 0.79 [0.64; 0.98]
IMpower-131 (ACnP), 2020 0.88 [0.73; 1.06]
IMpower-150 (ABCP vs BPC WT), 2018 0.78 [0.64; 0.96]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.76 [0.63; 0.92]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.85 [0.71; 1.02]
KEYNOTE-021, 2016 0.90 [0.42; 1.92]
KEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88]
KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93]
KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92]
KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85]
KEYNOTE-189, 2018 0.49 [0.38; 0.64]
KEYNOTE-407, 2018 0.64 [0.49; 0.84]
KEYNOTE-598, 2020 1.08 [0.85; 1.37]
MYSTIC (D ; all population), 2020 0.96 [0.81; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03]
ORIENT-11, 2020 0.61 [0.40; 0.93]
0.78 [0.72 ; 0.84 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 25 56% 14,400 moderate critical deaths (OS) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08]
KEYNOTE-021, 2016 0.71 [0.45; 1.12]
KEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81]
KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90]
KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88]
KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18]
KEYNOTE-189, 2018 0.56 [0.45; 0.70]
0.74 [0.64 ; 0.85 ] IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 7 67% 3,940 moderate not evaluable PFS (extension)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86]
IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81]
KEYNOTE-021, 2016 0.54 [0.35; 0.83]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65]
KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18]
KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10]
KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01]
KEYNOTE-189, 2018 0.48 [0.40; 0.58]
0.69 [0.56 ; 0.85 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 9 90% 4,822 moderate serious progression or deaths (PFS)detailed results CheckMate 026 (PDL1>1%), 2016 1.17 [0.95; 1.44]
CheckMate 026 (PDL1>5%), 2016 1.15 [0.91; 1.45]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.73 [0.56; 0.95]
EMPOWER lung1 (all population), 2021 0.59 [0.49; 0.72]
EMPOWER lung1 (PDL1>50%), 2021 0.54 [0.43; 0.68]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94]
IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87]
IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88]
IMpower-130 (all population), 2019 0.65 [0.54; 0.78]
IMpower-130 (WT), 2019 0.64 [0.54; 0.76]
IMpower-131 (ACnP), 2020 0.71 [0.60; 0.85]
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 0.51 [0.38; 0.68]
IMpower-150 (ABCP vs BPC WT), 2018 0.62 [0.52; 0.74]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.61 [0.52; 0.72]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.91 [0.78; 1.06]
KEYNOTE-021, 2016 0.53 [0.31; 0.91]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68]
KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21]
KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11]
KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98]
KEYNOTE-189, 2018 0.52 [0.43; 0.63]
KEYNOTE-407, 2018 0.56 [0.45; 0.70]
KEYNOTE-598, 2020 1.06 [0.86; 1.30]
MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29]
ORIENT-11, 2020 0.48 [0.36; 0.64]
0.71 [0.64 ; 0.79 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 25 85% 13,934 moderate critical DORdetailed results IMpower-130 (WT), 2019 2.41 [1.27; 4.60]
IMpower-131 (ACnP), 2020 2.14 [1.13; 4.04]
2.27 [1.44 ; 3.57 ] IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020 2 0% 601 moderate not evaluable objective responses (ORR)detailed results CheckMate 026 (PDL1>5%), 2016 0.70 [0.46; 1.06]
EMPOWER lung1 (all population), 2021 2.21 [1.58; 3.10]
EMPOWER lung1 (PDL1>50%), 2021 2.53 [1.32; 4.85]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27]
IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50]
IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79]
IMpower-130 (WT), 2019 2.07 [1.48; 2.89]
IMpower-131 (ACnP), 2020 1.42 [1.05; 1.92]
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 1.96 [1.20; 3.19]
IMpower-150 (ABCP vs BPC WT), 2018 1.88 [1.38; 2.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.95 [1.47; 2.58]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 1.02 [0.77; 1.35]
KEYNOTE-021, 2016 3.06 [1.45; 6.45]
KEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39]
KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33]
KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66]
KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94]
KEYNOTE-189, 2018 3.88 [2.61; 5.79]
KEYNOTE-407, 2018 2.20 [1.57; 3.09]
KEYNOTE-598, 2020 1.00 [0.72; 1.39]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43]
ORIENT-11, 2020 2.54 [1.63; 3.97]
1.55 [1.30 ; 1.86 ] CheckMate 026 (PDL1>5%), 2016, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 22 81% 12,281 moderate low objective responses (ORR) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01]
KEYNOTE-021, 2016 2.80 [1.34; 5.83]
KEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02]
KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32]
KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62]
KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88]
KEYNOTE-189, 2018 3.84 [2.58; 5.70]
1.72 [1.20 ; 2.47 ] IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 7 84% 3,940 moderate not evaluable AE (any grade)detailed results EMPOWER lung1 (all population), 2021 0.18 [0.12; 0.27]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01]
IMpower-130 (all population), 2019 2.05 [0.29; 14.63]
IMpower-131 (ACnP), 2020 5.12 [1.11; 23.56]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.49 [0.15; 1.65]
KEYNOTE-189, 2018 4.04 [0.36; 44.82]
KEYNOTE-407, 2018 1.20 [0.36; 3.96]
MYSTIC (D ; all population), 2020 0.59 [0.31; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22]
ORIENT-11, 2020 1.02 [0.03; 30.46]
0.73 [0.37 ; 1.41 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 10 76% 6,003 moderate critical AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.19 [0.13; 0.29]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55]
IMpower-130 (all population), 2019 1.72 [1.19; 2.47]
IMpower-131 (ACnP), 2020 1.37 [0.98; 1.90]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.14 [0.86; 1.52]
KEYNOTE-189, 2018 1.03 [0.73; 1.45]
KEYNOTE-407, 2018 0.99 [0.70; 1.39]
MYSTIC (D ; all population), 2020 0.81 [0.60; 1.10]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41]
ORIENT-11, 2020 1.13 [0.74; 1.73]
0.84 [0.58 ; 1.22 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 10 91% 6,003 moderate low AE leading to death (grade 5)detailed results EMPOWER lung1 (all population), 2021 1.24 [0.46; 3.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15]
IMpower-130 (all population), 2019 0.94 [0.47; 1.87]
IMpower-131 (ACnP), 2020 2.59 [1.36; 4.92]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.10 [0.60; 2.03]
KEYNOTE-189, 2018 1.13 [0.56; 2.28]
KEYNOTE-407, 2018 1.31 [0.69; 2.49]
MYSTIC (D ; all population), 2020 0.82 [0.38; 1.75]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86]
ORIENT-11, 2020 0.31 [0.11; 0.90]
1.08 [0.79 ; 1.46 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 10 35% 6,003 moderate critical AE leading to treatment discontinuation (any grade)detailed results EMPOWER lung1 (all population), 2021 1.62 [0.82; 3.21]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61]
IMpower-130 (all population), 2019 1.27 [0.88; 1.85]
IMpower-131 (ACnP), 2020 2.09 [1.45; 3.02]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.46 [1.07; 1.99]
KEYNOTE-189, 2018 2.19 [1.31; 3.65]
KEYNOTE-407, 2018 2.28 [1.45; 3.61]
MYSTIC (D ; all population), 2020 0.72 [0.47; 1.12]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46]
ORIENT-11, 2020 0.70 [0.31; 1.55]
1.19 [0.84 ; 1.69 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 10 82% 6,003 moderate low AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-189, 2018 2.04 [1.16; 3.59]
KEYNOTE-407, 2018 2.09 [1.28; 3.39]
MYSTIC (D ; all population), 2020 1.10 [0.64; 1.89]
ORIENT-11, 2020 0.64 [0.26; 1.56]
1.43 [0.89 ; 2.29 ] KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 4 61% 2,283 low not evaluable SAE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44]
IMpower-130 (all population), 2019 1.69 [1.22; 2.32]
IMpower-131 (ACnP), 2020 2.28 [1.66; 3.14]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.40 [1.05; 1.87]
MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94]
1.48 [1.12 ; 1.95 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, MYSTIC (D ; PDL1>25%), 2020 5 69% 3,023 moderate not evaluable STRAE (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.93 [0.60; 1.46]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.75 [1.00; 3.09]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85]
IMpower-130 (all population), 2019 2.09 [1.35; 3.24]
IMpower-131 (ACnP), 2020 2.27 [1.46; 3.51]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.43 [1.02; 2.00]
KEYNOTE-021, 2016 3.47 [1.25; 9.62]
KEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82]
MYSTIC (D ; all population), 2020 0.56 [0.35; 0.90]
MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77]
1.14 [0.77 ; 1.68 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 10 83% 5,054 moderate low STRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.82 [0.50; 1.33]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.05 [1.12; 3.76]
KEYNOTE-021, 2016 5.56 [1.49; 20.67]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72]
MYSTIC (D ; all population), 2020 0.48 [0.28; 0.84]
1.16 [0.62 ; 2.15 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020 5 79% 2,031 moderate not evaluable TRAE (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.20 [0.12; 0.34]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 3.42 [1.76; 6.65]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40]
IMpower-130 (all population), 2019 2.00 [1.01; 3.95]
IMpower-131 (ACnP), 2020 1.80 [0.98; 3.28]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.81 [0.43; 1.53]
KEYNOTE-021, 2016 0.95 [0.29; 3.12]
KEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58]
KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26]
MYSTIC (D ; all population), 2020 0.24 [0.17; 0.34]
MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38]
0.53 [0.30 ; 0.95 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 11 93% 6,305 moderate critical TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.21 [0.14; 0.31]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.35 [1.53; 3.60]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29]
IMpower-130 (all population), 2019 1.79 [1.28; 2.50]
IMpower-131 (ACnP), 2020 1.57 [1.14; 2.15]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.38 [1.04; 1.83]
KEYNOTE-021, 2016 2.04 [0.92; 4.52]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51]
KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39]
MYSTIC (D ; all population), 2020 0.34 [0.24; 0.49]
MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61]
0.64 [0.36 ; 1.15 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 11 96% 6,305 moderate low TRAE leading to death (grade 5)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 4.33 [0.48; 39.16]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
IMpower-130 (all population), 2019 3.97 [0.49; 31.97]
IMpower-131 (ACnP), 2020 1.34 [0.30; 6.02]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01]
KEYNOTE-021, 2016 0.52 [0.05; 5.86]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11]
KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92]
KEYNOTE-407, 2018 1.70 [0.61; 4.75]
MYSTIC (D ; all population), 2020 0.63 [0.11; 3.82]
MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32]
1.15 [0.75 ; 1.74 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 11 0% 6,333 moderate low TRAE leading to discontinuation (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.70 [0.41; 1.20]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.89 [0.48; 1.63]
KEYNOTE-021, 2016 0.76 [0.25; 2.35]
KEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44]
KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39]
MYSTIC (D ; all population), 2020 0.55 [0.31; 0.99]
MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04]
0.75 [0.60 ; 0.94 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 7 0% 3,596 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.24 [0.64; 2.40]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.80 [0.38; 1.70]
KEYNOTE-021, 2016 4.44 [0.48; 40.91]
KEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29]
KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66]
MYSTIC (D ; all population), 2020 1.28 [0.60; 2.75]
1.09 [0.82 ; 1.45 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 6 0% 3,282 moderate not evaluable Acute kidney injury TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 4.32 [0.19; 97.73]
4.32 [0.19 ; 97.73 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.06; 16.09]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
KEYNOTE-189, 2018 0.50 [0.03; 8.00]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.36 [0.35 ; 5.34 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 5 0% 4,034 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.48 [0.12 ; 1.95 ] CheckMate 026 (PDL1>1%), 2016, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 7 0% 4,783 moderate serious Anaemia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.13]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.34 [0.75; 2.38]
IMpower-130 (all population), 2019 1.62 [1.11; 2.36]
IMpower-131 (ACnP), 2020 1.09 [0.76; 1.58]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.05 [0.58; 1.89]
KEYNOTE-021, 2016 0.79 [0.27; 2.29]
KEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28]
KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12]
MYSTIC (D ; all population), 2020 0.01 [0.00; 0.19]
0.35 [0.16 ; 0.76 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 9 91% 5,442 moderate serious Arthralgia TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.75 [0.17; 3.37]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.80 [0.21 ; 2.99 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,706 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.12 [0.01; 2.31]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.07; 17.15]
IMpower-130 (all population), 2019 1.48 [0.40; 5.52]
IMpower-131 (ACnP), 2020 0.77 [0.28; 2.10]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.45 [0.15; 1.30]
KEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05]
MYSTIC (D ; all population), 2020 0.12 [0.01; 0.94]
0.52 [0.29 ; 0.95 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 7 15% 5,017 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58]
1.00 [0.13 ; 7.77 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016 3 0% 955 moderate not evaluable Colitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-131 (ACnP), 2020 8.08 [0.43; 153.53]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.53 [0.49; 13.10]
KEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97]
KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87]
KEYNOTE-189, 2018 3.01 [0.15; 60.33]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
3.11 [1.23 ; 7.86 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 8 0% 5,584 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.26 [0.01; 5.89]
IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
IMpower-131 (ACnP), 2020 0.50 [0.02; 14.93]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
MYSTIC (D ; all population), 2020 0.48 [0.02; 14.24]
0.68 [0.20 ; 2.27 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 9 0% 5,442 moderate serious Decreased appetite TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.24 [0.03; 2.19]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48]
IMpower-130 (all population), 2019 0.86 [0.25; 2.95]
IMpower-131 (ACnP), 2020 3.41 [0.93; 12.49]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3.40 [0.93; 12.46]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27]
KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60]
MYSTIC (D ; all population), 2020 0.24 [0.03; 2.13]
0.95 [0.46 ; 1.96 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 9 41% 5,442 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 6.05 [0.30; 121.16]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
1.85 [0.39 ; 8.75 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 5 0% 3,087 moderate serious Diarrhoea TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.59 [0.14; 2.48]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.15; 7.64]
EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-130 (all population), 2019 1.03 [0.49; 2.14]
IMpower-131 (ACnP), 2020 1.44 [0.54; 3.83]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 5.64 [1.24; 25.63]
KEYNOTE-021, 2016 0.52 [0.02; 15.84]
KEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11]
KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77]
MYSTIC (D ; all population), 2020 0.95 [0.13; 6.81]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.35 [0.87 ; 2.09 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 11 0% 6,536 moderate low Dizziness TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.05 [0.02 ; 53.86 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.84 [0.12 ; 5.97 ] CheckMate 026 (PDL1>1%), 2016, IMpower-130 (all population), 2019, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016 4 0% 1,660 moderate not evaluable Epistaxis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59]
8.09 [0.43 ; 153.59 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.20 [0.06; 0.71]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.18 [0.65; 7.39]
IMpower-130 (all population), 2019 1.02 [0.53; 1.96]
IMpower-131 (ACnP), 2020 1.89 [0.75; 4.80]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.31 [0.57; 3.03]
KEYNOTE-021, 2016 4.32 [0.19; 97.73]
KEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00]
KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36]
MYSTIC (D ; all population), 2020 0.81 [0.27; 2.45]
0.91 [0.54 ; 1.51 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 9 45% 5,442 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 2.66 [1.10; 6.46]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.48 [0.85; 2.57]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
1.75 [1.10 ; 2.78 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 0% 1,576 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.19 [0.36; 3.94]
1.19 [0.36 ; 3.94 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
1.00 [0.02 ; 50.55 ] IMpower-131 (ACnP), 2020 1 0% 668 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87]
IMpower-131 (ACnP), 2020 1.00 [0.06; 16.05]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59]
KEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54]
KEYNOTE-189, 2018 4.02 [0.21; 76.41]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
4.87 [1.69 ; 14.02 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 7 0% 5,280 moderate not evaluable Hypertension TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.57; 1.78]
1.00 [0.57 ; 1.78 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.11 [0.34 ; 3.64 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 10 0% 6,102 moderate critical Hypophysitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
1.90 [0.40 ; 8.99 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 5 0% 3,670 moderate serious Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 4.02 [0.18; 89.44]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
MYSTIC (D ; all population), 2020 3.83 [0.17; 85.25]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.62 [0.55 ; 4.71 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 11 0% 6,632 moderate critical Increase AST TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63]
ORIENT-11, 2020 0.49 [0.01; 24.91]
2.07 [0.70 ; 6.13 ] EMPOWER lung1 (all population), 2021, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 5 0% 3,253 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 3.51 [0.72; 17.07]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26]
ORIENT-11, 2020 0.49 [0.01; 24.91]
2.10 [0.98 ; 4.51 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 6 0% 3,783 moderate not evaluable Increased lacrimation (TRAE grade 3-4)detailed results KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.05 [0.02 ; 53.86 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
0.55 [0.15 ; 2.03 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 6 0% 3,500 moderate serious Leucopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.05 [0.00; 0.92]
IMpower-131 (ACnP), 2020 1.46 [0.72; 2.93]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.77 [0.51; 6.09]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82]
0.65 [0.18 ; 2.35 ] CheckMate 026 (PDL1>1%), 2016, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019 5 61% 3,357 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.95 [0.18 ; 21.58 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021 2 0% 1,227 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
0.98 [0.02 ; 49.83 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Myalgia TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.18; 22.26]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.73 [0.30 ; 10.01 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,706 moderate not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
1.05 [0.16 ; 6.91 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018 4 0% 2,366 moderate not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.19 [0.02; 1.67]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.85 [0.22; 3.21]
IMpower-130 (all population), 2019 1.61 [0.52; 5.00]
IMpower-131 (ACnP), 2020 3.55 [0.73; 17.23]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.91 [0.80; 4.57]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.08 [0.00; 1.41]
0.83 [0.37 ; 1.88 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 9 48% 5,442 moderate serious Nephritis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 6.06 [0.34; 109.04]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
1.96 [0.52 ; 7.32 ] EMPOWER lung1 (all population), 2021, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 7 0% 5,035 moderate serious Neutropenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.25]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.19 [0.63; 2.24]
IMpower-130 (all population), 2019 1.22 [0.86; 1.72]
IMpower-131 (ACnP), 2020 0.93 [0.65; 1.35]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.27 [0.83; 1.94]
KEYNOTE-021, 2016 2.14 [0.19; 24.25]
KEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35]
KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14]
MYSTIC (D ; all population), 2020 0.02 [0.00; 0.18]
0.48 [0.25 ; 0.92 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 9 83% 5,442 moderate serious Pancreatitis TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.03 [0.18; 89.56]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
2.11 [0.47 ; 9.43 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 5 0% 3,617 moderate serious Pancytopenia TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 0.52 [0.02; 15.84]
0.52 [0.02 ; 15.84 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.50 [0.02; 14.97]
0.50 [0.02 ; 14.97 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-131 (ACnP), 2020 2.01 [0.37; 11.06]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76]
1.16 [0.56 ; 2.42 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-042 (PDL1>1%), 2019 5 0% 3,933 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.02 [0.06 ; 16.38 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-021, 2016 2 0% 651 moderate not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 4.04 [0.45; 36.31]
KEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43]
0.64 [0.01 ; 29.61 ] IMpower-131 (ACnP), 2020, KEYNOTE-042 (PDL1>1%), 2019 2 78% 1,919 moderate not evaluable Pneumonia TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 2.12 [0.07; 64.42]
2.12 [0.07 ; 64.42 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-131 (ACnP), 2020 1.68 [0.40; 7.07]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3.04 [0.61; 15.15]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97]
KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
MYSTIC (D ; all population), 2020 3.85 [0.43; 34.59]
ORIENT-11, 2020 0.98 [0.09; 10.96]
2.33 [1.26 ; 4.30 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 10 0% 6,102 moderate low Pruritus TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.02; 53.93]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.09 [0.24 ; 4.83 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 6 0% 3,375 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.66 [0.05 ; 8.61 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.98 [0.18; 21.94]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.13 [0.07; 64.04]
EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
IMpower-131 (ACnP), 2020 2.01 [0.18; 22.23]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.59 [0.99; 21.40]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
ORIENT-11, 2020 0.16 [0.02; 1.56]
2.02 [0.97 ; 4.21 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 10 0% 6,076 moderate low Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
1.97 [0.07 ; 59.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 12.07 [0.67; 217.19]
12.07 [0.67 ; 217.19 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Sepsis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
2.06 [0.19 ; 22.93 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 2 0% 908 moderate not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98]
KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
2.45 [0.73 ; 8.21 ] IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 5 30% 2,951 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 5.00 [0.58; 43.09]
5.00 [0.58 ; 43.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
KEYNOTE-021, 2016 0.52 [0.02; 15.84]
KEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
1.04 [0.27 ; 4.02 ] CheckMate 026 (PDL1>1%), 2016, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 5 0% 2,993 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.04 [0.01; 0.31]
IMpower-130 (all population), 2019 1.52 [0.83; 2.79]
IMpower-131 (ACnP), 2020 1.16 [0.68; 2.00]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.94 [0.47; 1.89]
KEYNOTE-021, 2016 1.05 [0.14; 7.73]
KEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75]
MYSTIC (D ; all population), 2020 0.03 [0.00; 0.42]
0.44 [0.19 ; 1.01 ] CheckMate 026 (PDL1>1%), 2016, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 8 74% 5,087 moderate serious Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.78 [0.08 ; 7.49 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 3 0% 2,162 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.10 [0.01; 1.78]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48]
IMpower-130 (all population), 2019 1.48 [0.40; 5.52]
IMpower-131 (ACnP), 2020 3.02 [0.31; 29.16]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.21 [0.37; 3.99]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.06; 15.71]
KEYNOTE-042 (PDL1>1%), 2019 0.24 [0.01; 5.36]
MYSTIC (D ; all population), 2020 0.07 [0.00; 1.18]
1.00 [0.51 ; 1.94 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 9 5% 5,442 moderate not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
KEYNOTE-407, 2018 10.24 [0.56; 188.30]
3.10 [0.49 ; 19.80 ] EMPOWER lung1 (all population), 2021, IMpower-130 (all population), 2019, KEYNOTE-407, 2018 3 0% 1,960 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.23 [0.24; 6.38]
1.23 [0.24 ; 6.38 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Agranulocytosis (AE grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Alopecia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
KEYNOTE-407, 2018 0.33 [0.03; 3.22]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.38 [0.08 ; 1.76 ] EMPOWER lung1 (all population), 2021, IMpower-130 (all population), 2019, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 4 0% 2,681 moderate not evaluable Anaemia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.03 [0.01; 0.13]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.08 [0.03; 0.20]
IMpower-130 (all population), 2019 1.47 [1.03; 2.11]
KEYNOTE-189, 2018 1.07 [0.67; 1.71]
KEYNOTE-407, 2018 0.72 [0.46; 1.11]
KEYNOTE-598, 2020 1.14 [0.41; 3.20]
MYSTIC (D ; all population), 2020 0.16 [0.07; 0.34]
0.39 [0.17 ; 0.87 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; all population), 2020 7 92% 4,400 moderate serious Arthralgia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-130 (all population), 2019 7.97 [0.46; 139.30]
KEYNOTE-407, 2018 2.03 [0.37; 11.17]
KEYNOTE-598, 2020 2.01 [0.36; 11.05]
2.12 [0.74 ; 6.09 ] EMPOWER lung1 (all population), 2021, IMpower-130 (all population), 2019, KEYNOTE-407, 2018, KEYNOTE-598, 2020 4 0% 2,523 low not evaluable Asthenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.36 [0.07; 1.89]
IMpower-130 (all population), 2019 1.59 [0.58; 4.39]
KEYNOTE-189, 2018 1.83 [0.78; 4.31]
KEYNOTE-407, 2018 0.60 [0.21; 1.66]
KEYNOTE-598, 2020 0.25 [0.03; 2.22]
MYSTIC (D ; all population), 2020 0.95 [0.41; 2.23]
0.97 [0.60 ; 1.57 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; all population), 2020 7 13% 4,400 moderate not evaluable Back pain AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-130 (all population), 2019 3.97 [0.49; 31.97]
KEYNOTE-598, 2020 0.50 [0.04; 5.51]
MYSTIC (D ; all population), 2020 0.32 [0.03; 3.05]
0.87 [0.25 ; 3.00 ] EMPOWER lung1 (all population), 2021, IMpower-130 (all population), 2019, KEYNOTE-598, 2020, MYSTIC (D ; all population), 2020 4 4% 2,686 moderate not evaluable Blood creatinine increased AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.04 [0.10 ; 10.25 ] EMPOWER lung1 (all population), 2021, IMpower-130 (all population), 2019 2 0% 1,402 moderate not evaluable Colitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 2.96 [0.15; 59.25]
KEYNOTE-407, 2018 2.04 [0.50; 8.23]
2.18 [0.61 ; 7.72 ] IMpower-130 (all population), 2019, KEYNOTE-407, 2018 2 0% 1,263 low not evaluable Constipation AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
IMpower-130 (all population), 2019 4.95 [0.27; 90.93]
KEYNOTE-189, 2018 2.00 [0.22; 18.06]
KEYNOTE-407, 2018 0.67 [0.11; 4.04]
KEYNOTE-598, 2020 1.00 [0.14; 7.12]
MYSTIC (D ; all population), 2020 0.95 [0.06; 15.31]
1.24 [0.53 ; 2.89 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; all population), 2020 7 0% 4,400 low not evaluable Cough AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.84 [0.06; 55.14]
IMpower-130 (all population), 2019 2.96 [0.15; 59.25]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
KEYNOTE-407, 2018 0.67 [0.11; 4.04]
KEYNOTE-598, 2020 0.50 [0.02; 14.89]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.00 [0.31 ; 3.18 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; all population), 2020 6 0% 3,703 low not evaluable Decreased appetite AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-130 (all population), 2019 0.98 [0.33; 2.90]
KEYNOTE-189, 2018 3.02 [0.36; 25.28]
KEYNOTE-407, 2018 1.21 [0.37; 4.02]
KEYNOTE-598, 2020 6.03 [0.30; 120.98]
MYSTIC (D ; all population), 2020 1.44 [0.40; 5.14]
1.40 [0.76 ; 2.56 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; all population), 2020 7 0% 4,400 moderate serious Diabetes mellitus AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Diarrhoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.16 [0.02; 1.32]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.01; 5.09]
IMpower-130 (all population), 2019 0.87 [0.44; 1.70]
KEYNOTE-189, 2018 1.79 [0.71; 4.50]
KEYNOTE-407, 2018 1.88 [0.69; 5.16]
KEYNOTE-598, 2020 10.29 [1.31; 80.96]
MYSTIC (D ; all population), 2020 0.38 [0.07; 1.96]
1.07 [0.51 ; 2.26 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; all population), 2020 7 54% 4,400 moderate not evaluable Dizziness AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dry skin AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dysgeusia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dyspnoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.17; 21.41]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-130 (all population), 2019 5.61 [1.31; 24.06]
KEYNOTE-189, 2018 0.67 [0.30; 1.48]
KEYNOTE-407, 2018 3.04 [0.31; 29.44]
KEYNOTE-598, 2020 0.87 [0.31; 2.43]
MYSTIC (D ; all population), 2020 1.61 [0.58; 4.47]
1.41 [0.77 ; 2.60 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; all population), 2020 7 28% 4,400 low serious Epistaxis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
KEYNOTE-407, 2018 1.01 [0.02; 50.94]
0.62 [0.06 ; 6.00 ] IMpower-130 (all population), 2019, KEYNOTE-407, 2018 2 0% 1,263 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-15 04:20 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
